Comparison of Total Leukocyte Chimerism and Lymphocyte Subset Chimerism for Early Detection of Post-Transplant Complications
TRANSPLANT IMMUNOLOGY, cilt.95, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 95
- Basım Tarihi: 2026
- Doi Numarası: 10.1016/j.trim.2026.102361
- Dergi Adı: TRANSPLANT IMMUNOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO)
- İstanbul Üniversitesi Adresli: Evet
Özet
Purpose: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with risks of GVHD, graft rejection, and relapse. Chimerism monitoring supports early detection, though the prognostic value of B- and Tcell chimerism remains unclear. We aimed to compare total leukocyte chimerism with lymphocyte subset chimerism to determine their clinical utility in predicting relapse, GVHD, and overall survival (OS) in allo-HSCT recipients. Methods: Patients with hematologic malignancies who underwent allo-HSCT from an HLA-matched sibling or unrelated donor were included. Total leukocyte, B-cell, and T-cell chimerism were analyzed on days 28 and 90 post-transplant. DNA was isolated using a DTAB/CTAB-based method, and chimerism was determined via STRPCR and capillary electrophoresis. Associations with relapse, GVHD, and event-free survival (EFS) were evaluated. Statistical analysis was performed using SPSS v21.0, including Fisher's exact test, Mann-Whitney U test, and Kaplan-Meier survival analysis. Results: Among 21 allo-HSCT recipients, full donor chimerism (FDC) was observed in 95.2% and mixed chimerism (MC) in 4.8%. Most patients with acute (52.4%) and chronic GVHD (47.6%), relapse (4.8%), or death (19.0%) had FDC. These patterns were consistent across B, T, and total leukocyte subsets on days 28 and 90. Mean disease-free survival was 8.7 months; OS was 11.3 months. No statistically significant association was found between chimerism type and relapse, GVHD, or survival. EFS also did not differ between FDC and MC. Conclusions: Lineage-specific chimerism analysis may enhance early detection of post-transplant complications and improve monitoring precision. However, its clinical utility requires validation in larger cohorts.